Lymphangitis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Lymphangitis most often is an acute complication following an extension from the skin infection with the potential of a systemic spread. It has to be promptly treated with appropriate [[antibiotics]] along with [[analgesics]], [[anti inflammatory medications]], warm and moist compresses | Lymphangitis most often is an acute complication following an extension from the skin infection with the potential of a systemic spread. It has to be promptly treated with appropriate [[antibiotics]] along with [[analgesics]], [[anti inflammatory medications]], warm and moist compresses. | ||
==Principles of Therapy== | ==Principles of Therapy== |
Revision as of 17:03, 4 June 2014
Lymphangitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Lymphangitis medical therapy On the Web |
American Roentgen Ray Society Images of Lymphangitis medical therapy |
Risk calculators and risk factors for Lymphangitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vendhan Ramanujam M.B.B.S [2]
Overview
Lymphangitis most often is an acute complication following an extension from the skin infection with the potential of a systemic spread. It has to be promptly treated with appropriate antibiotics along with analgesics, anti inflammatory medications, warm and moist compresses.
Principles of Therapy
- Prompt empirical antibiotic therapy that mostly covers beta-hemolytic streptococci should be started in order to prevent the rapid progression of lymphangitis.
- If the patients do not respond to the initial empirical antibiotic therapy or present with a systemic toxicity, then empiric coverage to methicillin-resistant staphylococcus aureus (MRSA) should be considered.
- Patients with mild to moderate disease can be managed in an outpatient setting and patients with severe disease should be managed in an inpatient setting.
- While treating the patients with antibiotics, the following should be considered
- Carbapenems should not be used in patients with a history of hypersensitivity to beta-lactams.
- TMP-SMX is not recommended for women in the third trimester of pregnancy and in children under 2 months of age.
- Tetracyclines should not be used in children under 8 years of age.
- Besides antibiotics, analgesics, anti inflammatory medications, hot and moist compresses can be used to control pain and inflammation.
- Chronic sporotrichoid form of lymphangitis can be treated with chemotherapy.
- Recurrent lymphangitis can lead to chronic lymphedema, which can be treated with leg elevation, intermittent pneumatic compressions, manual massages, and multilayered bandage wrapping.
Therapy Based on Clinical Form
Acute Lymphangitis
Empiric Therapy
▸ Click on the following categories to expand treatment regimens.[1][2]
Mild - Moderate Acute Lymphangitis ▸ Adults ▸ Children age >28 days Severe Acute Lymphangitis ▸ Adults ▸ Children age >28 days |
|
Pathogen Based Therapy
▸ Click on the following categories to expand treatment regimens.[1][2]
Bacteria ▸ Streptococcus Pyogenes ▸ Methicillin Sensitive Staphylococcus Aureus ▸ Methicillin Resistant Staphylococcus Aureus ▸ Pasteurella Multocida |
|
Chronic Lymphangitis
Pathogen Based Therapy
▸ Click on the following categories to expand treatment regimens.[3][4][5]
Bacteria ▸ Mycobacterium Marinum Fungi ▸ Sporothrix Schenckii Parasites ▸ Brugia Malayi ▸ Wuchereria Bancrofti |
|
|
|
|
References
- ↑ 1.0 1.1 Moran GJ, Abrahamian FM, Lovecchio F, Talan DA (2013). "Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines". J Emerg Med. 44 (6): e397–412. doi:10.1016/j.jemermed.2012.11.050. PMID 23466022.
- ↑ 2.0 2.1 Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ; et al. (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clin Infect Dis. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910.
- ↑ Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America (2007). "Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (10): 1255–65. doi:10.1086/522765. PMID 17968818.
- ↑ Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F; et al. (2007). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". Am J Respir Crit Care Med. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. PMID 17277290.
- ↑ "Parasites - Lymphatic Filariasis".